BR112019001794A2 - composição de cannabis - Google Patents

composição de cannabis

Info

Publication number
BR112019001794A2
BR112019001794A2 BR112019001794-1A BR112019001794A BR112019001794A2 BR 112019001794 A2 BR112019001794 A2 BR 112019001794A2 BR 112019001794 A BR112019001794 A BR 112019001794A BR 112019001794 A2 BR112019001794 A2 BR 112019001794A2
Authority
BR
Brazil
Prior art keywords
cancer
cannabis composition
pharmaceutical composition
relates
associated symptom
Prior art date
Application number
BR112019001794-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Karelis Harry
Gordon Mara
Smith Stewart
Washer Stewart
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65524553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019001794(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2017901222A external-priority patent/AU2017901222A0/en
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of BR112019001794A2 publication Critical patent/BR112019001794A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112019001794-1A 2016-08-03 2017-08-03 composição de cannabis BR112019001794A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662370299P 2016-08-03 2016-08-03
US62/370,299 2016-08-03
AU2017901222 2017-04-04
AU2017901222A AU2017901222A0 (en) 2017-04-04 Cannabis composition
AU2017902065A AU2017902065A0 (en) 2017-05-31 Cannabis composition
AU2017902065 2017-05-31
PCT/AU2017/050817 WO2018023166A1 (en) 2016-08-03 2017-08-03 Cannabis composition

Publications (1)

Publication Number Publication Date
BR112019001794A2 true BR112019001794A2 (pt) 2019-05-07

Family

ID=65524553

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001794-1A BR112019001794A2 (pt) 2016-08-03 2017-08-03 composição de cannabis

Country Status (15)

Country Link
US (2) US11304925B1 (https=)
EP (1) EP3493800A4 (https=)
JP (2) JP2019526541A (https=)
KR (3) KR20220132674A (https=)
CN (1) CN109789123A (https=)
AU (4) AU2017305103B2 (https=)
BR (1) BR112019001794A2 (https=)
CA (1) CA3031300A1 (https=)
CL (1) CL2019000266A1 (https=)
CO (1) CO2019001043A2 (https=)
IL (1) IL264458B (https=)
MX (1) MX386086B (https=)
PE (2) PE20200677A1 (https=)
SG (1) SG11201900501RA (https=)
WO (1) WO2018023166A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900665VA (en) 2016-08-03 2019-02-27 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
BR112019026877A2 (pt) 2017-06-19 2020-06-30 Zelda Therapeutics Operations Pty Ltd composições para distúrbios do sono e tratamentos do mesmo
US10668044B2 (en) * 2017-06-27 2020-06-02 William H. Muscarella Blended cannabis compounds and methods of making the same
AU2018101357B4 (en) * 2017-09-15 2022-03-17 Zelira Therapeutics Operations Pty Ltd Composition and method for treating autism
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
AU2019251357B2 (en) * 2018-04-09 2023-10-05 Portland Technology Holdings Llc Hemp extract for treatment of pain in animals
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
EP3807385A1 (en) * 2018-06-14 2021-04-21 Biosoma B.V. Process for the extraction of oil-soluble components from plant material
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
WO2020084423A1 (en) * 2018-10-24 2020-04-30 Radient Technologies Innovations Inc. Extraction-based contract execution
EP3893868A4 (en) * 2018-12-12 2022-08-10 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN T-CELL LYMPHOMA (CTCL)
NL2022615B1 (en) * 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
WO2020211915A1 (en) * 2019-04-17 2020-10-22 Nordiccan A/S Fast disintegrating cannabinoid tablets
CA3154295A1 (en) * 2019-10-09 2021-04-15 Michael Foster DAVIS Aerosolisable material
CN118161552A (zh) * 2019-12-19 2024-06-11 史蒂文·罗斯斯坦 富含多酚化合物的提取物以及相关方法
CA3181384A1 (en) * 2020-04-29 2021-11-04 Ligar Limited Partnership Imprinted polymers and methods for their use
EP4146193A4 (en) * 2020-05-04 2024-05-29 Agronomed Management, LLC Topical anti-inflammatory cannabinoid compositions
MX2022015799A (es) * 2020-06-12 2023-04-11 Zelira Therapeutics Operations Pty Ltd Composicion y metodo para el tratamiento del dolor cronico.
WO2022191551A1 (ko) * 2021-03-08 2022-09-15 주식회사 엘지생활건강 칸나비게롤을 포함하는 조성물
IL307444A (en) * 2021-04-05 2023-12-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Preparations and methods for the treatment of cancer
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2025231524A1 (en) * 2024-05-08 2025-11-13 Heyday RX Pty Ltd Cannabinoid compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
EP1827393A4 (en) * 2004-12-09 2012-04-18 Insys Therapeutics Inc AT ROOM TEMPERATURE, STABLE DRONABINOL FORMULATIONS
US20070060639A1 (en) 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
US8980940B2 (en) * 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
WO2013165251A1 (en) * 2012-05-03 2013-11-07 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising /\9-tetrahydrocannabinol and a method for preparing such an isolate
EP2968259B1 (en) * 2013-03-14 2022-09-14 SC Laboratories Inc. Bioactive concentrates and uses thereof
WO2014145490A2 (en) 2013-03-15 2014-09-18 Biotech Institute, Llc Breeding, production, processing and use of specialty cannabis
HRP20221172T1 (hr) 2013-10-29 2023-02-03 Biotech Institute, Llc Uzgoj, proizvodnja, prerada i uporaba specijalnog sinsemilla kanabisa
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
AU2015308546A1 (en) * 2014-08-25 2017-04-13 Clk Consult V/ Carsten Leonhard Knudsen Device with compositions for delivery to the lungs, the oral mucosa and the brain
BR122021018502B1 (pt) * 2014-10-21 2022-05-03 United Cannabis Corp Formulação de canabinoide líquida
MX395015B (es) 2014-12-12 2025-03-24 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
WO2016105514A1 (en) * 2014-12-23 2016-06-30 Biotech Institute, Llc A reliable and robust method for the analysis of cannabinoids and terpenes in cannabis
CA2974292C (en) 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
JP2019523282A (ja) 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
SG11201900665VA (en) 2016-08-03 2019-02-27 Zelda Therapeutics Operations Pty Ltd Cannabis composition

Also Published As

Publication number Publication date
KR20190034576A (ko) 2019-04-02
AU2021205115B2 (en) 2023-06-15
PE20230607A1 (es) 2023-04-13
KR20210129747A (ko) 2021-10-28
AU2017305103A1 (en) 2018-07-05
CL2019000266A1 (es) 2019-10-04
KR102447510B1 (ko) 2022-09-27
JP2019526541A (ja) 2019-09-19
SG11201900501RA (en) 2019-02-27
AU2017305103B2 (en) 2019-02-21
AU2019203529A1 (en) 2019-06-06
WO2018023166A1 (en) 2018-02-08
IL264458A (en) 2019-02-28
AU2021205115A1 (en) 2021-08-12
PE20200677A1 (es) 2020-06-11
JP7139559B2 (ja) 2022-09-21
NZ750272A (en) 2021-09-24
KR20220132674A (ko) 2022-09-30
CN109789123A (zh) 2019-05-21
MX2019001286A (es) 2019-06-13
US11304925B1 (en) 2022-04-19
AU2019203529B2 (en) 2021-04-29
JP2021054836A (ja) 2021-04-08
EP3493800A4 (en) 2020-04-08
AU2018100920B4 (en) 2019-02-07
CO2019001043A2 (es) 2020-06-19
CA3031300A1 (en) 2018-02-08
MX386086B (es) 2025-03-18
EP3493800A1 (en) 2019-06-12
IL264458B (en) 2021-06-30
AU2018100920A4 (en) 2018-08-02
US20220202767A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
BR112019001794A2 (pt) composição de cannabis
BR112019000690A2 (pt) composição auto-emulsificante de alta concentração, forma de dosagem oral de alta resistência e método de tratamento de um sintoma, doença ou distúrbio responsivo ao canabinóide
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2019000268A1 (es) Composición de cannabis.
BR112019001852A2 (pt) composição de cannabis
CL2017002998A1 (es) Plantas que tienen expresión modificada de thca sintasa
BR112017008301A2 (pt) extratos de cannabis e métodos de sua preparação e uso
CL2019003635A1 (es) Composiciones y tratamientos para el trastorno del sueño.
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
MX381302B (es) Hidrogenación de aceite de cannabis.
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112017027836A2 (pt) método para o tratamento de inflamação usando compostos naturais e/ou dieta
BR112016018085A8 (pt) composições sinérgicas de suplemento dietético para prevenção, tratamento ou controle de doenças inflamatórias e respectivo método de aplicação das composições sinérgicas
BR112016025876A8 (pt) composição, processos para preparar uma microcápsula e uma forma de dosagem unitária, forma de dosagem unitária, microcápsula, produto, uso de uma composição, e, método para tratar uma condição associada à vitamina k1 ou k2
BR112017021191A2 (pt) um extrato de indigo naturalis e um processo para preparar o mesmo
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
BR112019008516A2 (pt) derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo
BR112016029619A2 (pt) novas fluoroquinolonas e sesu usos no tratamento de infecções bacterianas
BR112015022571A2 (pt) método de tratamento de esteatose hepática

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.